Full Text:
<1065>
Summary: 
<442>
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2022-10-13
Cited: 0
Clicked: 1255
Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy
| ||||||||||||||
Delin KONG, Tingting YANG, Jia GENG, Ruirui JING, Qiqi ZHANG, Guoqing WEI, He HUANG, Yongxian HU. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy[J]. Journal of Zhejiang University Science B, 2022, 23(10): 876-880.
@article{title="Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy",
author="Delin KONG, Tingting YANG, Jia GENG, Ruirui JING, Qiqi ZHANG, Guoqing WEI, He HUANG, Yongxian HU",
journal="Journal of Zhejiang University Science B",
volume="23",
number="10",
pages="876-880",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200128"
}
%0 Journal Article
%T Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy
%A Delin KONG
%A Tingting YANG
%A Jia GENG
%A Ruirui JING
%A Qiqi ZHANG
%A Guoqing WEI
%A He HUANG
%A Yongxian HU
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 10
%P 876-880
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200128
TY - JOUR
T1 - Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy
A1 - Delin KONG
A1 - Tingting YANG
A1 - Jia GENG
A1 - Ruirui JING
A1 - Qiqi ZHANG
A1 - Guoqing WEI
A1 - He HUANG
A1 - Yongxian HU
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 10
SP - 876
EP - 880
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200128
Abstract: Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10%‒20% (Nguyen et al., 2008; Oriol et al., 2010). extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15% to 20% of all relapsed patients (Ding et al., 2017; Sun et al., 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL. In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is extremely poor (Spyridonidis et al., 2012; Dahlberg et al., 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.
[1]BrudnoJN, SomervilleRPT, ShiV, et al., 2016. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol, 34(10):1112-1121.
[2]CruzCRY, MicklethwaiteKP, SavoldoB, et al., 2013. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 122(17):2965-2973.
[3]DahlbergA, LeisenringW, BleakleyM, et al., 2019. Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children. Bone Marrow Transplant, 54(8):1337-1345.
[4]DingLW, SunQY, MayakondaA, et al., 2017. Mutational profiling of acute lymphoblastic leukemia with testicular relapse. J Hematol Oncol, 10:65.
[5]FabrizioVA, PhillipsCL, LaneA, et al., 2022. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a pediatric real world CAR consortium report. Blood Adv, 6(2):600-610.
[6]GauthierJ, BezerraED, HirayamaAV, et al., 2021. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 137(3):323-335.
[7]HuangH, WuHW, HuYX, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):29-41.
[8]KochenderferJN, DudleyME, CarpenterRO, et al., 2013. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 122(25):4129-4139.
[9]LeeDW, KochenderferJN, Stetler-StevensonM, et al., 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385(9967):517-528.
[10]MaudeSL, FreyN, ShawPA, et al., 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 371(16):1507-1517.
[11]MaudeSL, LaetschTW, BuechnerJ, et al., 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 378(5):439-448.
[12]NguyenK, DevidasM, ChengSC, et al., 2008. Factors influencing survival after relapse from acute lymphoblastic leukemia: a children’s oncology group study. Leukemia, 22(12):2142-2150.
[13]OriolA, VivesS, Hernández-RivasJM, et al., 2010. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica, 95(4):589-596.
[14]ParkJH, RiviereI, GonenM, et al., 2018. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med, 378(5):449-459.
[15]SpyridonidisA, LabopinM, SchmidC, et al., 2012. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the acute leukemia working party of EBMT. Leukemia, 26(6):1211-1217.
[16]SunWL, MalvarJ, SpostoR, et al., 2018. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia, 32(11):2316-2325.
[17]TalekarMK, MaudeSL, HucksGE, et al., 2017. Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). J Clin Oncol, 35(15 Suppl):10507-10507.
[18]TurtleCJ, HanafiLA, BergerC, et al., 2016. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest, 126(6):2123-2138.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>